JP4580341B2 - 管腔内プロテーゼ及びこれに薬剤を含浸させる二酸化炭素アシスト方法。 - Google Patents

管腔内プロテーゼ及びこれに薬剤を含浸させる二酸化炭素アシスト方法。 Download PDF

Info

Publication number: JP4580341B2
Authority: JP; Japan
Prior art keywords: drug; carrier fluid; polymeric material; endoluminal prosthesis; layered polymeric
Prior art date: 2002-11-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

JP2005507054A

Other languages

English (en)

Japanese (ja)

Other versions

JP2006512175A (ja

Inventor

ウィリアムズ，マイケル・エス

デシモーネ，ジョゼフ・エム

Original Assignee

サインコア，リミテッド・ライアビリティ・カンパニー

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-11-14

Filing date

2003-10-23

Publication date

2010-11-10

2003-10-23 Application filed by サインコア，リミテッド・ライアビリティ・カンパニー filed Critical サインコア，リミテッド・ライアビリティ・カンパニー

2006-04-13 Publication of JP2006512175A publication Critical patent/JP2006512175A/ja

2010-11-10 Application granted granted Critical

2010-11-10 Publication of JP4580341B2 publication Critical patent/JP4580341B2/ja

2023-10-23 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

229940079593 drug Drugs 0.000 title claims description 122
239000003814 drug Substances 0.000 title claims description 122
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 title claims description 102
238000000034 method Methods 0.000 title claims description 57
239000001569 carbon dioxide Substances 0.000 title claims description 51
229910002092 carbon dioxide Inorganic materials 0.000 title claims description 51
239000000463 material Substances 0.000 claims description 123
239000012530 fluid Substances 0.000 claims description 74
239000000203 mixture Substances 0.000 claims description 25
239000003795 chemical substances by application Substances 0.000 claims description 23
229920000642 polymer Polymers 0.000 claims description 20
239000007789 gas Substances 0.000 claims description 13
238000000576 coating method Methods 0.000 claims description 12
230000008859 change Effects 0.000 claims description 11
239000011248 coating agent Substances 0.000 claims description 11
239000000126 substance Substances 0.000 claims description 10
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims description 8
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims description 7
229960005167 everolimus Drugs 0.000 claims description 7
239000011241 protective layer Substances 0.000 claims description 7
239000004094 surface-active agent Substances 0.000 claims description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
238000010828 elution Methods 0.000 claims description 6
238000009792 diffusion process Methods 0.000 claims description 5
239000002904 solvent Substances 0.000 claims description 5
229910052786 argon Inorganic materials 0.000 claims description 4
239000006184 cosolvent Substances 0.000 claims description 4
239000001307 helium Substances 0.000 claims description 4
229910052734 helium Inorganic materials 0.000 claims description 4
SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 claims description 4
229910052757 nitrogen Inorganic materials 0.000 claims description 4
239000011261 inert gas Substances 0.000 claims description 3
230000000873 masking effect Effects 0.000 claims description 3
239000012190 activator Substances 0.000 claims 2
239000010410 layer Substances 0.000 description 32
239000012528 membrane Substances 0.000 description 30
239000000843 powder Substances 0.000 description 11
239000002245 particle Substances 0.000 description 10
238000012377 drug delivery Methods 0.000 description 8
239000007788 liquid Substances 0.000 description 8
230000002209 hydrophobic effect Effects 0.000 description 7
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 6
230000003902 lesion Effects 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
229930012538 Paclitaxel Natural products 0.000 description 5
239000003146 anticoagulant agent Substances 0.000 description 5
239000002246 antineoplastic agent Substances 0.000 description 5
229960001592 paclitaxel Drugs 0.000 description 5
239000002861 polymer material Substances 0.000 description 5
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 5
238000011282 treatment Methods 0.000 description 5
230000001070 adhesive effect Effects 0.000 description 4
238000002399 angioplasty Methods 0.000 description 4
210000004204 blood vessel Anatomy 0.000 description 4
-1 captopril (eg Chemical compound 0.000 description 4
208000037803 restenosis Diseases 0.000 description 4
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 3
102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 3
108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 3
239000002202 Polyethylene glycol Substances 0.000 description 3
RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 3
239000000853 adhesive Substances 0.000 description 3
239000004019 antithrombin Substances 0.000 description 3
210000001367 artery Anatomy 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
229920001577 copolymer Polymers 0.000 description 3
238000006731 degradation reaction Methods 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
230000035699 permeability Effects 0.000 description 3
229920001432 poly(L-lactide) Polymers 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
230000002265 prevention Effects 0.000 description 3
230000008569 process Effects 0.000 description 3
239000000758 substrate Substances 0.000 description 3
230000002792 vascular Effects 0.000 description 3
210000005166 vasculature Anatomy 0.000 description 3
IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
108010092160 Dactinomycin Proteins 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 2
PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 2
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
239000004952 Polyamide Substances 0.000 description 2
229920000954 Polyglycolide Polymers 0.000 description 2
229920000331 Polyhydroxybutyrate Polymers 0.000 description 2
RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 2
230000001464 adherent effect Effects 0.000 description 2
239000002998 adhesive polymer Substances 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
230000000702 anti-platelet effect Effects 0.000 description 2
230000001028 anti-proliverative effect Effects 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
229940127219 anticoagulant drug Drugs 0.000 description 2
239000003080 antimitotic agent Substances 0.000 description 2
229940041181 antineoplastic drug Drugs 0.000 description 2
TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
239000000824 cytostatic agent Substances 0.000 description 2
230000001085 cytostatic effect Effects 0.000 description 2
229960003957 dexamethasone Drugs 0.000 description 2
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
229940126864 fibroblast growth factor Drugs 0.000 description 2
230000009477 glass transition Effects 0.000 description 2
239000003966 growth inhibitor Substances 0.000 description 2
WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
239000000017 hydrogel Substances 0.000 description 2
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
230000007774 longterm Effects 0.000 description 2
PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
229960004857 mitomycin Drugs 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
230000003647 oxidation Effects 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
239000005015 poly(hydroxybutyrate) Substances 0.000 description 2
229920002647 polyamide Polymers 0.000 description 2
229920000728 polyester Polymers 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
KWPACVJPAFGBEQ-IKGGRYGDSA-N (2s)-1-[(2r)-2-amino-3-phenylpropanoyl]-n-[(3s)-1-chloro-6-(diaminomethylideneamino)-2-oxohexan-3-yl]pyrrolidine-2-carboxamide Chemical compound C([C@@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)CCl)C1=CC=CC=C1 KWPACVJPAFGBEQ-IKGGRYGDSA-N 0.000 description 1
PUDHBTGHUJUUFI-SCTWWAJVSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-p Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 PUDHBTGHUJUUFI-SCTWWAJVSA-N 0.000 description 1
GQGRDYWMOPRROR-ZIFKCHSBSA-N (e)-7-[(1r,2r,3s,5s)-3-hydroxy-5-[(4-phenylphenyl)methoxy]-2-piperidin-1-ylcyclopentyl]hept-4-enoic acid Chemical compound O([C@H]1C[C@@H]([C@@H]([C@H]1CC\C=C\CCC(O)=O)N1CCCCC1)O)CC(C=C1)=CC=C1C1=CC=CC=C1 GQGRDYWMOPRROR-ZIFKCHSBSA-N 0.000 description 1
150000000094 1,4-dioxanes Chemical class 0.000 description 1
KZDCPJDWDXMJRA-UHFFFAOYSA-N 2-hydroxybutanoic acid;pentanoic acid Chemical compound CCCCC(O)=O.CCC(O)C(O)=O KZDCPJDWDXMJRA-UHFFFAOYSA-N 0.000 description 1
SFIUYASDNWEYDB-HHQFNNIRSA-N 6-chloro-1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine-7-sulfonamide;(2s)-1-[(2s)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O.C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O SFIUYASDNWEYDB-HHQFNNIRSA-N 0.000 description 1
VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
239000005541 ACE inhibitor Substances 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
229940127291 Calcium channel antagonist Drugs 0.000 description 1
229920001661 Chitosan Polymers 0.000 description 1
JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
229920000742 Cotton Polymers 0.000 description 1
SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
229920000219 Ethylene vinyl alcohol Polymers 0.000 description 1
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
108010007267 Hirudins Proteins 0.000 description 1
102000007625 Hirudins Human genes 0.000 description 1
102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
102000006992 Interferon-alpha Human genes 0.000 description 1
108010047761 Interferon-alpha Proteins 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
108010007859 Lisinopril Proteins 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
229930192392 Mitomycin Natural products 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
229920001244 Poly(D,L-lactide) Polymers 0.000 description 1
229920002732 Polyanhydride Polymers 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
229920001710 Polyorthoester Polymers 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
208000000453 Skin Neoplasms Diseases 0.000 description 1
229940122388 Thrombin inhibitor Drugs 0.000 description 1
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
230000009471 action Effects 0.000 description 1
239000011149 active material Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
229940009456 adriamycin Drugs 0.000 description 1
229920003232 aliphatic polyester Polymers 0.000 description 1
229940003354 angiomax Drugs 0.000 description 1
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
230000003266 anti-allergic effect Effects 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229940124599 anti-inflammatory drug Drugs 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
239000000043 antiallergic agent Substances 0.000 description 1
238000011319 anticancer therapy Methods 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
229940127218 antiplatelet drug Drugs 0.000 description 1
229960004676 antithrombotic agent Drugs 0.000 description 1
KXNPVXPOPUZYGB-XYVMCAHJSA-N argatroban Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[C@H](C)C2 KXNPVXPOPUZYGB-XYVMCAHJSA-N 0.000 description 1
229960003856 argatroban Drugs 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
YEESUBCSWGVPCE-UHFFFAOYSA-N azanylidyneoxidanium iron(2+) pentacyanide Chemical compound [Fe++].[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.N#[O+] YEESUBCSWGVPCE-UHFFFAOYSA-N 0.000 description 1
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
229960002170 azathioprine Drugs 0.000 description 1
230000008901 benefit Effects 0.000 description 1
229960002537 betamethasone Drugs 0.000 description 1
UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
210000003445 biliary tract Anatomy 0.000 description 1
229920002988 biodegradable polymer Polymers 0.000 description 1
239000004621 biodegradable polymer Substances 0.000 description 1
WMWLMWRWZQELOS-UHFFFAOYSA-N bismuth(III) oxide Inorganic materials O=[Bi]O[Bi]=O WMWLMWRWZQELOS-UHFFFAOYSA-N 0.000 description 1
108010055460 bivalirudin Proteins 0.000 description 1
OIRCOABEOLEUMC-GEJPAHFPSA-N bivalirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 OIRCOABEOLEUMC-GEJPAHFPSA-N 0.000 description 1
229920001400 block copolymer Polymers 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
239000000480 calcium channel blocker Substances 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
229940097633 capoten Drugs 0.000 description 1
229960000830 captopril Drugs 0.000 description 1
210000000748 cardiovascular system Anatomy 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
239000000919 ceramic Substances 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
HHHKFGXWKKUNCY-FHWLQOOXSA-N cilazapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 HHHKFGXWKKUNCY-FHWLQOOXSA-N 0.000 description 1
229960005025 cilazapril Drugs 0.000 description 1
229960001338 colchicine Drugs 0.000 description 1
OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
238000000748 compression moulding Methods 0.000 description 1
238000010924 continuous production Methods 0.000 description 1
229940088547 cosmegen Drugs 0.000 description 1
229960000640 dactinomycin Drugs 0.000 description 1
230000006837 decompression Effects 0.000 description 1
CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
229960002768 dipyridamole Drugs 0.000 description 1
IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
229960003668 docetaxel Drugs 0.000 description 1
229960002918 doxorubicin hydrochloride Drugs 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
230000007071 enzymatic hydrolysis Effects 0.000 description 1
238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
229960001123 epoprostenol Drugs 0.000 description 1
KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
230000003628 erosive effect Effects 0.000 description 1
210000003238 esophagus Anatomy 0.000 description 1
239000005038 ethylene vinyl acetate Substances 0.000 description 1
239000004715 ethylene vinyl alcohol Substances 0.000 description 1
238000001125 extrusion Methods 0.000 description 1
210000001105 femoral artery Anatomy 0.000 description 1
229950003499 fibrin Drugs 0.000 description 1
239000010419 fine particle Substances 0.000 description 1
235000021323 fish oil Nutrition 0.000 description 1
NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
229920002313 fluoropolymer Polymers 0.000 description 1
239000004811 fluoropolymer Substances 0.000 description 1
229960002949 fluorouracil Drugs 0.000 description 1
235000013305 food Nutrition 0.000 description 1
230000006870 function Effects 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
239000002628 heparin derivative Substances 0.000 description 1
229960001008 heparin sodium Drugs 0.000 description 1
RZXDTJIXPSCHCI-UHFFFAOYSA-N hexa-1,5-diene-2,5-diol Chemical compound OC(=C)CCC(O)=C RZXDTJIXPSCHCI-UHFFFAOYSA-N 0.000 description 1
229940006607 hirudin Drugs 0.000 description 1
229920001519 homopolymer Polymers 0.000 description 1
229960000890 hydrocortisone Drugs 0.000 description 1
229910052588 hydroxylapatite Inorganic materials 0.000 description 1
229960001680 ibuprofen Drugs 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
208000033065 inborn errors of immunity Diseases 0.000 description 1
229960000905 indomethacin Drugs 0.000 description 1
238000001746 injection moulding Methods 0.000 description 1
230000003993 interaction Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
150000002596 lactones Chemical class 0.000 description 1
108010021336 lanreotide Proteins 0.000 description 1
229960002437 lanreotide Drugs 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000002502 liposome Substances 0.000 description 1
229960002394 lisinopril Drugs 0.000 description 1
RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
229960004844 lovastatin Drugs 0.000 description 1
QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
239000003055 low molecular weight heparin Substances 0.000 description 1
229940127215 low-molecular weight heparin Drugs 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
239000003120 macrolide antibiotic agent Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
102000006240 membrane receptors Human genes 0.000 description 1
108020004084 membrane receptors Proteins 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
239000007769 metal material Substances 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
229960004584 methylprednisolone Drugs 0.000 description 1
229940099246 mevacor Drugs 0.000 description 1
239000004530 micro-emulsion Substances 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
229960001597 nifedipine Drugs 0.000 description 1
HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
229960002460 nitroprusside Drugs 0.000 description 1
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
229940012843 omega-3 fatty acid Drugs 0.000 description 1
235000020660 omega-3 fatty acid Nutrition 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
239000000106 platelet aggregation inhibitor Substances 0.000 description 1
229920000118 poly(D-lactic acid) Polymers 0.000 description 1
229920001308 poly(aminoacid) Polymers 0.000 description 1
229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
229920000747 poly(lactic acid) Polymers 0.000 description 1
229920002463 poly(p-dioxanone) polymer Polymers 0.000 description 1
229920002627 poly(phosphazenes) Polymers 0.000 description 1
229920000058 polyacrylate Polymers 0.000 description 1
229920001610 polycaprolactone Polymers 0.000 description 1
229920000515 polycarbonate Polymers 0.000 description 1
239000004417 polycarbonate Substances 0.000 description 1
239000000622 polydioxanone Substances 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920000139 polyethylene terephthalate Polymers 0.000 description 1
239000005020 polyethylene terephthalate Substances 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
229920001299 polypropylene fumarate Polymers 0.000 description 1
NMMVKSMGBDRONO-UHFFFAOYSA-N potassium;9-methyl-3-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)pyrido[1,2-a]pyrimidin-4-one Chemical group [K+].CC1=CC=CN(C2=O)C1=NC=C2C1=NN=N[N-]1 NMMVKSMGBDRONO-UHFFFAOYSA-N 0.000 description 1
208000028529 primary immunodeficiency disease Diseases 0.000 description 1
229940117265 prinzide Drugs 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
150000003815 prostacyclins Chemical class 0.000 description 1
239000002089 prostaglandin antagonist Substances 0.000 description 1
238000005086 pumping Methods 0.000 description 1
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
238000012216 screening Methods 0.000 description 1
229940076279 serotonin Drugs 0.000 description 1
229910001285 shape-memory alloy Inorganic materials 0.000 description 1
229960002930 sirolimus Drugs 0.000 description 1
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
201000000849 skin cancer Diseases 0.000 description 1
210000000329 smooth muscle myocyte Anatomy 0.000 description 1
239000000243 solution Substances 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
229960005314 suramin Drugs 0.000 description 1
FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
229940037128 systemic glucocorticoids Drugs 0.000 description 1
229940063683 taxotere Drugs 0.000 description 1
229920001897 terpolymer Polymers 0.000 description 1
238000012360 testing method Methods 0.000 description 1
239000003868 thrombin inhibitor Substances 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000009827 uniform distribution Methods 0.000 description 1
210000003708 urethra Anatomy 0.000 description 1
229950007952 vapiprost Drugs 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
229960003048 vinblastine Drugs 0.000 description 1
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
229960004528 vincristine Drugs 0.000 description 1
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1

Images

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheets or tubes, e.g. perforated by laser cuts or etched holes
- A61F2/915—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheets or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheets or tubes, e.g. perforated by laser cuts or etched holes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/18—Materials at least partially X-ray or laser opaque
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheets or tubes, e.g. perforated by laser cuts or etched holes
- A61F2/915—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheets or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
- A61F2002/91533—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheets or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other characterised by the phase between adjacent bands
- A61F2002/91541—Adjacent bands are arranged out of phase
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheets or tubes, e.g. perforated by laser cuts or etched holes
- A61F2/915—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheets or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
- A61F2002/9155—Adjacent bands being connected to each other
- A61F2002/91575—Adjacent bands being connected to each other connected peak to trough
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2230/0002—Two-dimensional shapes, e.g. cross-sections
- A61F2230/0004—Rounded shapes, e.g. with rounded corners
- A61F2230/0013—Horseshoe-shaped, e.g. crescent-shaped, C-shaped, U-shaped
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0014—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
- A61F2250/0068—Means for introducing or releasing pharmaceutical products into the body the pharmaceutical product being in a reservoir
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/18—Modification of implant surfaces in order to improve biocompatibility, cell growth, fixation of biomolecules, e.g. plasma treatment
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T156/00—Adhesive bonding and miscellaneous chemical manufacture
- Y10T156/10—Methods of surface bonding and/or assembly therefor

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Animal Behavior & Ethology (AREA)
Biomedical Technology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Surgery (AREA)
Epidemiology (AREA)
Optics & Photonics (AREA)
Physics & Mathematics (AREA)
Oral & Maxillofacial Surgery (AREA)
Cardiology (AREA)
Transplantation (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Chemical & Material Sciences (AREA)
Materials For Medical Uses (AREA)
Prostheses (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Application Of Or Painting With Fluid Materials (AREA)

JP2005507054A 2002-11-14 2003-10-23 管腔内プロテーゼ及びこれに薬剤を含浸させる二酸化炭素アシスト方法。 Expired - Fee Related JP4580341B2 (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US42612502P	2002-11-14	2002-11-14
US10/662,757 US20040098106A1 (en)	2002-11-14	2003-09-15	Intraluminal prostheses and carbon dioxide-assisted methods of impregnating same with pharmacological agents
PCT/US2003/033645 WO2004043506A1 (fr)	2002-11-14	2003-10-23	Protheses intraluminales et leurs procedes d'impregnation avec des agents pharmacologiques faisant intervenir du dioxyde de carbone

Publications (2)

Publication Number	Publication Date
JP2006512175A JP2006512175A (ja)	2006-04-13
JP4580341B2 true JP4580341B2 (ja)	2010-11-10

Family

ID=32302668

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2005507054A Expired - Fee Related JP4580341B2 (ja)	2002-11-14	2003-10-23	管腔内プロテーゼ及びこれに薬剤を含浸させる二酸化炭素アシスト方法。

Country Status (6)

Country	Link
US (2)	US20040098106A1 (fr)
EP (1)	EP1560610A4 (fr)
JP (1)	JP4580341B2 (fr)
AU (1)	AU2003286631B2 (fr)
CA (1)	CA2501016C (fr)
WO (1)	WO2004043506A1 (fr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU716005B2 (en) *	1995-06-07	2000-02-17	Cook Medical Technologies Llc	Implantable medical device
US11243494B2 (en)	2002-07-31	2022-02-08	Abs Global, Inc.	Multiple laminar flow-based particle and cellular separation with laser steering
US7169178B1 (en) *	2002-11-12	2007-01-30	Advanced Cardiovascular Systems, Inc.	Stent with drug coating
US20060121087A1 (en) *	2004-12-06	2006-06-08	Williams Michael S	Polymeric endoprostheses with modified erosion rates and methods of manufacture
WO2007011707A2 (fr) *	2005-07-15	2007-01-25	Micell Technologies, Inc.	Enrobages polymeres renfermant de la poudre de medicament a morphologie commandee
WO2007011708A2 (fr)	2005-07-15	2007-01-25	Micell Technologies, Inc.	Stent a revetement polymere renfermant de la rapamycine amorphe
US20070196423A1 (en) *	2005-11-21	2007-08-23	Med Institute, Inc.	Implantable medical device coatings with biodegradable elastomer and releasable therapeutic agent
JP5102200B2 (ja) *	2006-03-30	2012-12-19	テルモ株式会社	生体内留置物
WO2007116646A1 (fr) *	2006-04-04	2007-10-18	Terumo Kabushiki Kaisha	Sonde à demeure in vivo
WO2007127362A2 (fr) *	2006-04-26	2007-11-08	The Cleveland Clinic Foundation	Appareil et procédé de traitement de maladies cardiovasculaires
US8652201B2 (en)	2006-04-26	2014-02-18	The Cleveland Clinic Foundation	Apparatus and method for treating cardiovascular diseases
ES2540059T3 (es)	2006-04-26	2015-07-08	Micell Technologies, Inc.	Recubrimientos que contienen múltiples fármacos
CA2667228C (fr)	2006-10-23	2015-07-14	Micell Technologies, Inc.	Support pour charger electriquement un substrat au cours de l'enduction
WO2008076383A2 (fr) *	2006-12-18	2008-06-26	Med Institute Inc.	Stent à agent thérapeutique libérable
JP5288370B2 (ja) *	2006-12-27	2013-09-11	独立行政法人産業技術総合研究所	生理活性物質を含む樹脂組成物とその製造方法
US11426494B2 (en)	2007-01-08	2022-08-30	MT Acquisition Holdings LLC	Stents having biodegradable layers
CA2679712C (fr)	2007-01-08	2016-11-15	Micell Technologies, Inc.	Stents comportant des couches biodegradables
AU2008256684B2 (en)	2007-05-25	2012-06-14	Micell Technologies, Inc.	Polymer films for medical device coating
US8425591B1 (en)	2007-06-11	2013-04-23	Abbott Cardiovascular Systems Inc.	Methods of forming polymer-bioceramic composite medical devices with bioceramic particles
US20090286907A1 (en) *	2008-01-23	2009-11-19	Beltz Mark W	Fumaric Acid/Diol Polyesters and Their Manufacture and Use
US20090192583A1 (en) *	2008-01-28	2009-07-30	Medtronic Vascular, Inc.	Ordered Coatings for Drug Eluting Stents and Medical Devices
US8053020B2 (en) *	2008-02-28	2011-11-08	Cook Medical Technologies Llc	Process for coating a portion of an implantable medical device
CN102083397B (zh)	2008-04-17	2013-12-25	米歇尔技术公司	具有生物可吸收层的支架
JP2011528275A (ja)	2008-07-17	2011-11-17	ミセルテクノロジーズ，インク．	薬物送達医療デバイス
US8642063B2 (en) *	2008-08-22	2014-02-04	Cook Medical Technologies Llc	Implantable medical device coatings with biodegradable elastomer and releasable taxane agent
US8076529B2 (en)	2008-09-26	2011-12-13	Abbott Cardiovascular Systems, Inc.	Expandable member formed of a fibrous matrix for intraluminal drug delivery
US8226603B2 (en)	2008-09-25	2012-07-24	Abbott Cardiovascular Systems Inc.	Expandable member having a covering formed of a fibrous matrix for intraluminal drug delivery
US8049061B2 (en)	2008-09-25	2011-11-01	Abbott Cardiovascular Systems, Inc.	Expandable member formed of a fibrous matrix having hydrogel polymer for intraluminal drug delivery
US8834913B2 (en)	2008-12-26	2014-09-16	Battelle Memorial Institute	Medical implants and methods of making medical implants
WO2010120552A2 (fr)	2009-04-01	2010-10-21	Micell Technologies, Inc.	Endoprothèses enduites
EP3366326A1 (fr)	2009-04-17	2018-08-29	Micell Technologies, Inc.	Endoprothèses vasculaires ayant une élution contrôlée
EP2453834A4 (fr)	2009-07-16	2014-04-16	Micell Technologies Inc	Dispositif médical distributeur de médicament
US20110059139A1 (en) *	2009-09-08	2011-03-10	Hillerstroem Anna	Method for loading a molecule into a porous substrate
EP2338534A2 (fr) *	2009-12-21	2011-06-29	Biotronik VI Patent AG	Implant médical, procédé de revêtement et procédé d'implantation
EP2531140B1 (fr)	2010-02-02	2017-11-01	Micell Technologies, Inc.	Endoprothèse et système de pose d'endoprothèse avec une capacité améliorée de pose
WO2011119536A1 (fr)	2010-03-22	2011-09-29	Abbott Cardiovascular Systems Inc.	Système de pose d'endoprothèse pourvu d'une matrice fibreuse ayant une capacité de rétention améliorée de l'endoprothèse
US8795762B2 (en)	2010-03-26	2014-08-05	Battelle Memorial Institute	System and method for enhanced electrostatic deposition and surface coatings
EP2560576B1 (fr)	2010-04-22	2018-07-18	Micell Technologies, Inc.	Endoprothèses et autres dispositifs ayant un revêtement de matrice extracellulaire
US20120010691A1 (en) *	2010-07-06	2012-01-12	Medtronic Vascular, Inc.	Particle Embedded Polymer Stent and Method of Manufacture
WO2012009684A2 (fr)	2010-07-16	2012-01-19	Micell Technologies, Inc.	Dispositif médical d'administration de médicament
US10908066B2 (en)	2010-11-16	2021-02-02	1087 Systems, Inc.	Use of vibrational spectroscopy for microfluidic liquid measurement
WO2012166819A1 (fr)	2011-05-31	2012-12-06	Micell Technologies, Inc.	Système et procédé de formation de revêtement transférable à élution de médicament, libéré dans le temps
CA2841360A1 (fr)	2011-07-15	2013-01-24	Micell Technologies, Inc.	Dispositif medical d'administration de medicament
US10188772B2 (en)	2011-10-18	2019-01-29	Micell Technologies, Inc.	Drug delivery medical device
KR20150143476A (ko)	2013-03-12	2015-12-23	미셀 테크놀로지즈, 인코포레이티드	생흡수성 생체의학적 임플란트
HK1222313A1 (zh)	2013-05-15	2017-06-30	Micell Technologies, Inc.	可生物吸收的生物医学植入物
US8961904B2 (en)	2013-07-16	2015-02-24	Premium Genetics (Uk) Ltd.	Microfluidic chip
US11796449B2 (en)	2013-10-30	2023-10-24	Abs Global, Inc.	Microfluidic system and method with focused energy apparatus
SG10201908628QA (en) *	2015-03-19	2019-11-28	Univ Nanyang Tech	A stent assembly and method of preparing the stent assembly
US11331670B2 (en)	2018-05-23	2022-05-17	Abs Global, Inc.	Systems and methods for particle focusing in microchannels
EP3899489B1 (fr)	2018-12-21	2025-04-09	ABS Global, Inc.	Système et procédés pour identification de sous-populations
EP3955735B1 (fr)	2019-04-18	2024-05-22	ABS Global, Inc.	Système et procédé d'ajout en continu de cryoprotecteur
US11628439B2 (en)	2020-01-13	2023-04-18	Abs Global, Inc.	Single-sheath microfluidic chip
WO2022087299A1 (fr)	2020-10-21	2022-04-28	Abs Global, Inc.	Procédés et systèmes de traitement d'échantillons génétiques pour déterminer l'identité ou détecter une contamination
US12135270B2 (en)	2020-11-23	2024-11-05	Abs Global, Inc.	Modular flow cytometry systems and methods of processing samples
US11497834B1 (en) *	2021-11-02	2022-11-15	Bio Protectant Technologies, Inc.	Supercritical method of making a biocompatible composite implant
USD1118965S1 (en)	2021-11-12	2026-03-17	Abs Global, Inc.	Flow cytometry device
CN121059904B (zh) *	2025-11-10	2026-01-27	哈尔滨瀚邦生物制药有限公司	一种基于超临界流体技术的猪胶原蛋白化学脱细胞方法

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4351337A (en) *	1973-05-17	1982-09-28	Arthur D. Little, Inc.	Biodegradable, implantable drug delivery device, and process for preparing and using the same
US5059211A (en) *	1987-06-25	1991-10-22	Duke University	Absorbable vascular stent
US5527337A (en) *	1987-06-25	1996-06-18	Duke University	Bioabsorbable stent and method of making the same
WO1990001969A1 (fr) *	1988-08-24	1990-03-08	Slepian Marvin J	Etancheification a l'aide d'un polymere biodegradable de la surface interieure d'une lumiere d'un organe
US5085629A (en) *	1988-10-06	1992-02-04	Medical Engineering Corporation	Biodegradable stent
CH678393A5 (fr) *	1989-01-26	1991-09-13	Ulrich Prof Dr Med Sigwart
US4994033A (en) *	1989-05-25	1991-02-19	Schneider (Usa) Inc.	Intravascular drug delivery dilatation catheter
CA2017332A1 (fr) *	1989-06-29	1990-12-29	Richard W. Greiner	Catheters impregnes d'un produit pharmaceutique
US5674192A (en) *	1990-12-28	1997-10-07	Boston Scientific Corporation	Drug delivery
US5545208A (en) *	1990-02-28	1996-08-13	Medtronic, Inc.	Intralumenal drug eluting prosthesis
US5258020A (en) *	1990-09-14	1993-11-02	Michael Froix	Method of using expandable polymeric stent with memory
JP2842943B2 (ja) *	1991-03-08	1999-01-06	敬二伊垣	脈管ステントとその保持構造体および脈管ステント挿着装置
US5443498A (en) *	1991-10-01	1995-08-22	Cook Incorporated	Vascular stent and method of making and implanting a vacsular stent
WO1993006792A1 (fr) *	1991-10-04	1993-04-15	Scimed Life Systems, Inc.	Extenseur vasculaire biodegradable pour administration d'un medicament
US5500013A (en) *	1991-10-04	1996-03-19	Scimed Life Systems, Inc.	Biodegradable drug delivery vascular stent
CA2087132A1 (fr) *	1992-01-31	1993-08-01	Michael S. Williams	Moulage de maintien pouvant se fixer a l'interieur d'une lumiere organique
US5599352A (en) *	1992-03-19	1997-02-04	Medtronic, Inc.	Method of making a drug eluting stent
EP0566245B1 (fr) *	1992-03-19	1999-10-06	Medtronic, Inc.	Dilatateur intraluminal
US5591224A (en) *	1992-03-19	1997-01-07	Medtronic, Inc.	Bioelastomeric stent
JP3739411B2 (ja) *	1992-09-08	2006-01-25	敬二伊垣	脈管ステント及びその製造方法並びに脈管ステント装置
US5449382A (en) *	1992-11-04	1995-09-12	Dayton; Michael P.	Minimally invasive bioactivated endoprosthesis for vessel repair
US5340614A (en) *	1993-02-11	1994-08-23	Minnesota Mining And Manufacturing Company	Methods of polymer impregnation
US5456917A (en) *	1993-04-12	1995-10-10	Cambridge Scientific, Inc.	Method for making a bioerodible material for the sustained release of a medicament and the material made from the method
US5441515A (en) *	1993-04-23	1995-08-15	Advanced Cardiovascular Systems, Inc.	Ratcheting stent
ATE169483T1 (de) *	1993-04-28	1998-08-15	Focal Inc	Vorrichtung, produkt und verwendung betreffend die intraluminale photothermoformgebung
US5417213A (en) *	1993-06-07	1995-05-23	Prince; Martin R.	Magnetic resonance arteriography with dynamic intravenous contrast agents
US5579767A (en) *	1993-06-07	1996-12-03	Prince; Martin R.	Method for imaging abdominal aorta and aortic aneurysms
US5590654A (en) *	1993-06-07	1997-01-07	Prince; Martin R.	Method and apparatus for magnetic resonance imaging of arteries using a magnetic resonance contrast agent
JP2703510B2 (ja) *	1993-12-28	1998-01-26	アドヴァンスドカーディオヴァスキュラーシステムズインコーポレーテッド	拡大可能なステント及びその製造方法
US5788687A (en) *	1994-02-01	1998-08-04	Caphco, Inc	Compositions and devices for controlled release of active ingredients
US5629077A (en) *	1994-06-27	1997-05-13	Advanced Cardiovascular Systems, Inc.	Biodegradable mesh and film stent
AU699821B2 (en) *	1994-10-17	1998-12-17	Kabushikikaisha Igaki Iryo Sekkei	Stent for liberating drug
US5549662A (en) *	1994-11-07	1996-08-27	Scimed Life Systems, Inc.	Expandable stent using sliding members
US5605696A (en) *	1995-03-30	1997-02-25	Advanced Cardiovascular Systems, Inc.	Drug loaded polymeric material and method of manufacture
US5591199A (en) *	1995-06-07	1997-01-07	Porter; Christopher H.	Curable fiber composite stent and delivery system
AU716005B2 (en) *	1995-06-07	2000-02-17	Cook Medical Technologies Llc	Implantable medical device
US5609629A (en) *	1995-06-07	1997-03-11	Med Institute, Inc.	Coated implantable medical device
EP0830109B1 (fr) *	1995-06-08	2003-10-15	Ave Galway Limited	Prothese endovasculaire bifurquee
US5744958A (en) *	1995-11-07	1998-04-28	Iti Medical Technologies, Inc.	Instrument having ultra-thin conductive coating and method for magnetic resonance imaging of such instrument
US5741293A (en) *	1995-11-28	1998-04-21	Wijay; Bandula	Locking stent
US5808060A (en) *	1995-12-11	1998-09-15	Cephalon, Inc.	Fused isoindolones
US5723508A (en) *	1996-01-25	1998-03-03	Northwestern University	Method of fabricating emulsion freeze-dried scaffold bodies and resulting products
US5670161A (en) *	1996-05-28	1997-09-23	Healy; Kevin E.	Biodegradable stent
US5916585A (en) *	1996-06-03	1999-06-29	Gore Enterprise Holdings, Inc.	Materials and method for the immobilization of bioactive species onto biodegradable polymers
US6232434B1 (en) *	1996-08-02	2001-05-15	Duke University Medical Center	Polymers for delivering nitric oxide in vivo
US5770645A (en) *	1996-08-02	1998-06-23	Duke University Medical Center	Polymers for delivering nitric oxide in vivo
US5868781A (en) *	1996-10-22	1999-02-09	Scimed Life Systems, Inc.	Locking stent
US5860467A (en) *	1996-12-03	1999-01-19	The University Of North Carolina At Chapel Hill	Use of CO2 -soluble materials in making molds
US5980972A (en) *	1996-12-20	1999-11-09	Schneider (Usa) Inc	Method of applying drug-release coatings
US5733330A (en) *	1997-01-13	1998-03-31	Advanced Cardiovascular Systems, Inc.	Balloon-expandable, crush-resistant locking stent
EP0916362B1 (fr) *	1997-03-31	2009-07-08	Kabushikikaisha Igaki Iryo Sekkei	Extenseur pour vaisseaux
US6272370B1 (en) *	1998-08-07	2001-08-07	The Regents Of University Of Minnesota	MR-visible medical device for neurological interventions using nonlinear magnetic stereotaxis and a method imaging
US6267769B1 (en) *	1997-05-15	2001-07-31	Regents Of The Universitiy Of Minnesota	Trajectory guide method and apparatus for use in magnetic resonance and computerized tomographic scanners
US6245103B1 (en) *	1997-08-01	2001-06-12	Schneider (Usa) Inc	Bioabsorbable self-expanding stent
US6174330B1 (en) *	1997-08-01	2001-01-16	Schneider (Usa) Inc	Bioabsorbable marker having radiopaque constituents
ATE236577T1 (de) *	1997-09-26	2003-04-15	Univ Duke	Katheter zur perfusion und okklusion
US5924987A (en) *	1997-10-06	1999-07-20	Meaney; James F. M.	Method and apparatus for magnetic resonance arteriography using contrast agents
US5957975A (en) *	1997-12-15	1999-09-28	The Cleveland Clinic Foundation	Stent having a programmed pattern of in vivo degradation
US6001418A (en) *	1997-12-16	1999-12-14	The University Of North Carolina At Chapel Hill	Spin coating method and apparatus for liquid carbon dioxide systems
US6179867B1 (en) *	1998-01-16	2001-01-30	Advanced Cardiovascular Systems, Inc.	Flexible stent and method of use
US6224626B1 (en) *	1998-02-17	2001-05-01	Md3, Inc.	Ultra-thin expandable stent
US6463317B1 (en) *	1998-05-19	2002-10-08	Regents Of The University Of Minnesota	Device and method for the endovascular treatment of aneurysms
US6139511A (en) *	1998-06-29	2000-10-31	Advanced Cardiovascular Systems, Inc.	Guidewire with variable coil configuration
JP4898991B2 (ja) *	1998-08-20	2012-03-21	クックメディカルテクノロジーズエルエルシー	被覆付植込式医療装置
US6120847A (en) *	1999-01-08	2000-09-19	Scimed Life Systems, Inc.	Surface treatment method for stent coating
US6368346B1 (en) *	1999-06-03	2002-04-09	American Medical Systems, Inc.	Bioresorbable stent
US6440405B1 (en) *	1999-06-07	2002-08-27	University Of Delaware	Quaternary ammonium functionalized dendrimers and methods of use therefor
EP1194428B1 (fr) *	1999-07-09	2003-09-17	3-Dimensional Pharmaceuticals, Inc.	Inhibiteurs de protease heteroaryle et agents d'imagerie diagnostique
EP1214108B1 (fr) *	1999-09-03	2007-01-10	Advanced Cardiovascular Systems, Inc.	Prothese poreuse et procede de depot de substances dans les pores
US6302907B1 (en) *	1999-10-05	2001-10-16	Scimed Life Systems, Inc.	Flexible endoluminal stent and process of manufacture
US7226475B2 (en) *	1999-11-09	2007-06-05	Boston Scientific Scimed, Inc.	Stent with variable properties
US6264671B1 (en) *	1999-11-15	2001-07-24	Advanced Cardiovascular Systems, Inc.	Stent delivery catheter and method of use
US6251136B1 (en) *	1999-12-08	2001-06-26	Advanced Cardiovascular Systems, Inc.	Method of layering a three-coated stent using pharmacological and polymeric agents
US6481262B2 (en) *	1999-12-30	2002-11-19	Advanced Cardiovascular Systems, Inc.	Stent crimping tool
US6264683B1 (en) *	2000-03-17	2001-07-24	Advanced Cardiovascular Systems, Inc.	Stent delivery catheter with bumpers for improved retention of balloon expandable stents
US6436132B1 (en) *	2000-03-30	2002-08-20	Advanced Cardiovascular Systems, Inc.	Composite intraluminal prostheses
US6627246B2 (en) *	2000-05-16	2003-09-30	Ortho-Mcneil Pharmaceutical, Inc.	Process for coating stents and other medical devices using super-critical carbon dioxide
JP2002035135A (ja) *	2000-07-31	2002-02-05	Manii Kk	ステント及びステントの製造方法
US6451373B1 (en) *	2000-08-04	2002-09-17	Advanced Cardiovascular Systems, Inc.	Method of forming a therapeutic coating onto a surface of an implantable prosthesis
CN1404405A (zh) *	2000-11-30	2003-03-19	株式会社伊垣医疗设计	血管用斯滕特固定模和用于血管斯滕特固定模的材料
US20020077691A1 (en) *	2000-12-18	2002-06-20	Advanced Cardiovascular Systems, Inc.	Ostial stent and method for deploying same
AU2002249826A1 (en) *	2000-12-22	2002-07-30	Avantec Vascular Corporation	Delivery of therapeutic capable agents
US20020082679A1 (en) *	2000-12-22	2002-06-27	Avantec Vascular Corporation	Delivery or therapeutic capable agents
DE10108581B4 (de) *	2001-02-22	2009-08-27	Mri Devices Daum Gmbh	Material für die Kernspintomographie
US6749628B1 (en) *	2001-05-17	2004-06-15	Advanced Cardiovascular Systems, Inc.	Stent and catheter assembly and method for treating bifurcations
US20030044514A1 (en) *	2001-06-13	2003-03-06	Richard Robert E.	Using supercritical fluids to infuse therapeutic on a medical device
US6945994B2 (en) *	2001-12-05	2005-09-20	Boston Scientific Scimed, Inc.	Combined balloon-expanding and self-expanding stent
US6932930B2 (en) *	2003-03-10	2005-08-23	Synecor, Llc	Intraluminal prostheses having polymeric material with selectively modified crystallinity and methods of making same

2003
- 2003-09-15 US US10/662,757 patent/US20040098106A1/en not_active Abandoned
- 2003-10-23 AU AU2003286631A patent/AU2003286631B2/en not_active Ceased
- 2003-10-23 CA CA2501016A patent/CA2501016C/fr not_active Expired - Fee Related
- 2003-10-23 EP EP03777837A patent/EP1560610A4/fr not_active Withdrawn
- 2003-10-23 WO PCT/US2003/033645 patent/WO2004043506A1/fr not_active Ceased
- 2003-10-23 JP JP2005507054A patent/JP4580341B2/ja not_active Expired - Fee Related
2011
- 2011-01-05 US US12/984,791 patent/US20110118824A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AU2003286631A1 (en)	2004-06-03
US20040098106A1 (en)	2004-05-20
WO2004043506A1 (fr)	2004-05-27
EP1560610A1 (fr)	2005-08-10
CA2501016A1 (fr)	2004-05-27
US20110118824A1 (en)	2011-05-19
AU2003286631B2 (en)	2009-02-05
EP1560610A4 (fr)	2010-11-03
JP2006512175A (ja)	2006-04-13
CA2501016C (fr)	2013-01-08

Legal Events

Date	Code	Title	Description
2006-10-21	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20061020
2009-09-14	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090911
2009-12-12	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091211
2009-12-21	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091218
2010-02-13	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100212
2010-02-22	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100219
2010-02-23	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100222
2010-08-11	TRDD	Decision of grant or rejection written
2010-08-16	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100813
2010-08-19	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01
2010-09-02	A61	First payment of annual fees (during grant procedure)	Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100827
2010-09-03	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20130903 Year of fee payment: 3
2010-09-03	R150	Certificate of patent or registration of utility model	Free format text: JAPANESE INTERMEDIATE CODE: R150
2013-09-03	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2014-09-02	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2015-09-01	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2016-09-03	LAPS	Cancellation because of no payment of annual fees

Publication	Publication Date	Title
JP4580341B2 (ja)	2010-11-10	管腔内プロテーゼ及びこれに薬剤を含浸させる二酸化炭素アシスト方法。
JP4617258B2 (ja)	2011-01-19	被検者の体内で使用される生体適合性ステントの製造方法
JP4836779B2 (ja)	2011-12-14	結晶度が選択的に変性された重合物質を有する管腔内プロテーゼ及びその製法
EP1684821B1 (fr)	2013-12-18	Revetements a effet biologiquement favorable pour dispositifs implantables contenant des polymeres fluores, et procede de fabrication de ces revetements
EP1684818B1 (fr)	2011-12-21	Revetements contenant des polyesters biologiquement erodables pour dispositifs implantables, ainsi que procedes de fabrication de ceux-ci
EP1517713B1 (fr)	2009-11-18	Enrobages d'endoprothese vasculaire a liberation medicamenteuse prolongee
US8501213B2 (en)	2013-08-06	Multiple drug delivery from a balloon and a prosthesis
US6585765B1 (en)	2003-07-01	Implantable device having substances impregnated therein and a method of impregnating the same
US9039748B2 (en)	2015-05-26	Method of securing a medical device onto a balloon and system thereof